国产药在去年上市新药中占比超85％

Core Viewpoint - In the past year, China has achieved record highs in the number of approved innovative drugs and total external licensing transactions, with approximately 30% of global drug pipelines currently under research in China. The National Medical Products Administration (NMPA) will continue to promote resources towards innovative drugs with new mechanisms and targets, while institutional support for biopharmaceutical innovation is expected to improve the domestic payment system for innovative drugs [3][4][6]. Group 1: Innovative Drug Approvals - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [3]. - Among the approved innovative drugs, domestic drugs accounted for over 85%, with 80.85% of chemical drugs and 91.30% of biological products being domestically developed [4][5]. - The quality of domestic drug development has improved, with China contributing nearly 50% to global early clinical pipelines for next-generation therapies like ADCs and bispecific/trispecific antibodies [5]. Group 2: Licensing Transactions - In 2025, the total amount of external licensing transactions for Chinese innovative drugs exceeded $130 billion, with over 150 transactions, doubling the previous year's total of $51.9 billion [6]. - The significant increase in licensing reflects international recognition of the value of Chinese innovative drugs, supported by ongoing reforms in drug review and approval processes [6][7]. Group 3: Policy and Market Environment - The NMPA plans to enhance support for urgently needed clinical drugs through expedited review channels and improve the protection of drug trial data and market exclusivity [7]. - The new foreign investment encouragement policy in the pharmaceutical sector signals China's openness to foreign capital in drug innovation, particularly in new target and mechanism development [8]. - Despite advancements, the market mechanisms for innovative drugs in China still require improvement, with current innovative drug market share at only 8.6% compared to 81.8% in the U.S., indicating a need for better payment and pricing structures [8][9]. Group 4: Market Growth Projections - A report predicts that the Chinese innovative drug market will reach approximately 550 billion RMB in 2024, growing to over 740 billion RMB in 2025, with a compound annual growth rate of 24.1% expected from 2024 to 2030 [10].